News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Adams Laboratories, Inc. Announces Initial Public Offering

10/19/2005 5:13:07 PM

CHESTER, N.J., March 25 /PRNewswire-FirstCall/ -- Adams Laboratories, Inc., a specialty pharmaceutical company, today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. A portion of the shares will be issued and sold by Adams Laboratories, and a portion will be sold by certain stockholders of Adams Laboratories.

Merrill Lynch & Co. and Morgan Stanley are acting as joint book-running managers for the offering. In addition, Deutsche Bank Securities and RBC Capital Markets are acting as co-managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

When available, copies of the preliminary prospectus relating to the offering may be obtained from: Merrill Lynch & Co., 4 World Financial Center, New York, New York 10080 (telephone: 212-449-1000) or Morgan Stanley, Prospectus Department, 1585 Broadway, New York, New York 10036 (telephone: 212-761-4000).

About Adams Laboratories, Inc.

Adams Laboratories is a specialty pharmaceutical company headquartered in Chester, New Jersey. Adams Laboratories currently markets two over-the-counter pharmaceuticals for the treatment of respiratory disorders under the Mucinex(R) brand name.

Contact Information: Investor Relations Robert Ferris 212-994-7505 Tom Pratt 212-994-7563 Media Relations Kajal Jhaveri 212-593-5864 847-331-4202

Adams Laboratories, Inc.

CONTACT: Investor Relations, Robert Ferris, +1-212-994-7505; or TomPratt, +1-212-994-7563, or Media Relations, Kajal Jhaveri, +1-212-593-5864, or+1-847-331-4202, all for Adams Laboratories, Inc.

Read at Reuters
Read at

comments powered by Disqus